Search

The utilization of quercetin nanoparticles as a novel therapeutic strategy has garnered significant attention in recent years. These nanoparticles offer a unique approach to enhancing delivery and effectiveness while overcoming the drawbacks of quercetin. By exploiting the advantages of nanotechnology, such as increased stability and improved bioavailability, quercetin nanoparticles hold significant potential for developing innovative treatments across various medical fields. Quercetin nanoparticles have emerged as an indispensable component in numerous pharmaceutical and medicinal formulations. They are recognized for their anticancer, antitumor, anti-inflammatory, and antidiabetic properties, making them valuable in addressing allergic reactions, metabolic disorders, inflammatory disorders, cardiovascular diseases, and arthritis. From a pharmacological perspective, quercetin nanoparticles have demonstrated beneficial effects against Alzheimer's disease, primarily through their inhibitory impact on acetylcholinesterase. Furthermore, these nanoparticles have been scientifically documented to possess antioxidant, anticarcinogenic, hepatoprotective, and cytotoxic activities. This comprehensive review aims to explore the pharmacokinetics and biological activities associated with quercetin nanoparticles. It also highlights their potential as therapeutic agents in treating a wide range of diseases, including Alzheimer's disease, cancer, and neurodegenerative disorders., Competing Interests: The author declared no potential conflicts of interest concerning this article’s research, authorship, and/or publication., (© 2024 Institute of Bioorganic Chemistry, Polish Academy of Sciences.)

The Pelvic Floor Disorders Consortium (PFDC) is a multidisciplinary organization of colorectal surgeons, urogynecologists, urologists, gynecologists, gastroenterologists, radiologists, physiotherapists, and other advanced care practitioners. Specialists from these fields are all dedicated to the diagnosis and management of patients with pelvic floor conditions, but they approach, evaluate, and treat such patients with their own unique perspectives given the differences in their respective training. The PFDC was formed to bridge gaps and enable collaboration between these specialties. The goal of the PFDC is to develop and evaluate educational programs, create clinical guidelines and algorithms, and promote high quality of care in this unique patient population. The recommendations included in this article represent the work of the PFDC Working Group on Magnetic Resonance Imaging of Pelvic Floor Disorders (members listed alphabetically in Table 1). The objective was to generate inclusive, rather than prescriptive, guidance for all practitioners, irrespective of discipline, involved in the evaluation and treatment of patients with pelvic floor disorders.